Apr 02, 2024 7:30am EDT Nexera to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mar 26, 2024 7:53am EDT FDA Approves Nexera's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Jan 08, 2024 7:00am EST Health Canada Accepts for Review Nexera's New Drug Submission for Topical Terbinafine
Nov 08, 2023 5:30pm EST Nexera Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
